MRNA Stock Moderna (MRNA, $25.13) Moving Average Convergence Divergence (MACD) Histogram turned positive on April 21, 2025

GET DAILY SIGNALS

Get AI intraday signals

MRNA - Moderna

MACD signal

View

Odds of UP Trend

Price: $25.13

Daily change: +$0.42 (+1.68%)

Daily volume: 6.9M

Capitalization: $9.6B

Industry: Biotechnology

MRNA in upward trend: price expected to rise as it breaks its lower Bollinger Band on March 31, 2025

MRNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 36 cases where MRNA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MRNA's RSI Indicator exited the oversold zone, of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on April 21, 2025. You may want to consider a long position or call options on MRNA as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for MRNA just turned positive on April 21, 2025. Looking at past instances where MRNA's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in of 278 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for MRNA entered a downward trend on April 16, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.971) is normal, around the industry mean (14.237). P/E Ratio (0.000) is within average values for comparable stocks, (63.881). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.827). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (3.287) is also within normal values, averaging (255.011).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.